C-5 substituted quinazolinone derivatives as selective...

Details C-5 substituted quinazolinone derivatives as selective... C-5 substituted quinazolinone derivatives as selective...

2006-04-26

2008-11-25

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S266310, C544S284000, C544S287000

Reexamination Certificate

active

07456188

ABSTRACT:
The present application describes compounds according to Formula I, wherein Q, R1, R2and X are described herein, that are useful as Estrogen Receptor Beta (ERβ) modulators. Additionally, the present application describes pharmaceutical compositions containing the compounds according to Formula I and optionally additional therapeutic agents. Finally, the present application describes methods utilizing the compounds according to Formula I for modulating the function of ERβ in the treatment of diseases and disorders associated with ERβ such as, for example, bone disorders; cardiovascular diseases; hypercholesterolemia; hypertriglyceridemia; vasomotor disorders; urogenital disorders; prostatic hypertrophy; endometrial hyperplasia; cancer and central nervous system disorders, such as, neurodegenerative disorders.

REFERENCES:
patent: 4411890 (1983-10-01), Momany
patent: 2003/0220227 (2003-11-01), Gungor et al.
patent: 10-259176 (1998-09-01), None
patent: WO 89/07110 (1989-08-01), None
patent: WO 89/07111 (1989-08-01), None
patent: WO 93/04081 (1993-03-01), None
patent: WO00/07996 (2000-02-01), None
Vippagunta, S.R. et al., “Crystalline solids”, Adv. Drug Del. Reviews, (2001), vol. 48, pp. 3-26.
Chemical Abstract, 1998, vol. 129, Abstract # 310895 (English Abstract for JP 10-259176).
Güngör, T. et al., “Synthesis and Characterization of 3-Arylquinazolinone and 3-Aryl1uinazolinethione Derivatives as Selective Estrogen Receptor Beta Modulators”, J. Med. Chem., vol. 49, pp. 2440-2455 (2006).
Sun, J. et al., “Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor-α or Estrogen Receptor-β*”, Endocrinology, vol. 140(2), pp. 800-804 (1999).
Zhou, H. et al., “Synthesis and Evaluation of Estrogen Receptor Ligands with Bridged Oxabicyclic Cores Containing a Diarylethylene Motif: Estrogen Antagonists of Unusual Structure”, J. Med. Chem., vol. 48, pp. 7261-7274 (2005).
Edwards, J.P. et al., “Nonsteroidal androgen receptor agonists based on 4-(Trifluoromethyl)-2H-Pyrano[3,2-g] Quinolin-2-One”, Bioorganic & Medicinal Chemistry Letters, vol. 9, pp. 1003-1008 (1999).
Hamann, L.G. et al., Discovery of a Potent, Orally Active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071), J. Med. Chem, (1999), vol. 42, pp. 210-212.
Kuiper, G. et al., “Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β”. Endocrinology, vol. 139(10), pp. 4252-4263 (1998).
Newman, H. et al., “The Synthesis of the Ring-B Sulfur Analog of Epigriseofulvin”, The J. of Organic Chemistry, vol. 34(11), pp. 3484-3491 (1969).

Affiliated with

Also associated with

Rating

C-5 substituted quinazolinone derivatives as selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with C-5 substituted quinazolinone derivatives as selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-5 substituted quinazolinone derivatives as selective... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4037919